Results
|
|
61.
|
|
|
|
62.
|
|
|
|
63.
|
|
|
|
64.
|
|
|
|
65.
|
|
|
|
66.
|
|
|
|
67.
|
|
|
|
68.
|
|
|
|
69.
|
|
|
|
70.
|
|
|
|
71.
|
|
|
|
72.
|
|
|
|
73.
|
|
|
|
74.
|
|
|
|
75.
|
|
|
|
76.
|
|
|
|
77.
|
|
|
|
78.
|
|
|
|
79.
|
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. [electronic resource] by
- Rutgeerts, P
- D'Haens, G
- Targan, S
- Vasiliauskas, E
- Hanauer, S B
- Present, D H
- Mayer, L
- Van Hogezand, R A
- Braakman, T
- DeWoody, K L
- Schaible, T F
- Van Deventer, S J
Producer: 19991028
In:
Gastroenterology vol. 117
Availability: No items available.
|
|
|
80.
|
The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. [electronic resource] by
- Lichtiger, S
- Binion, D G
- Wolf, D C
- Present, D H
- Bensimon, A G
- Wu, E
- Yu, A P
- Cardoso, A T
- Chao, J
- Mulani, P M
- Lomax, K G
- Kent, J D
Producer: 20110224
In:
Alimentary pharmacology & therapeutics vol. 32
Availability: No items available.
|